Cat. No.: HY-N2065

Withaferin A

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

Withaferin A is a steroidal lactone isolated from Withania somnifera, inhibits NF-kB activation and targets vimentin, with potent antiinflammatory and anticancer activities. Withaferin A is an inhibitor of endothelial protein C receptor (EPCR) shedding.

For research use only. We do not sell to patients.

Purity: 99.71%
CAS No.: 5119-48-2
Formula: C₂₈H₃₈O₆
Molecular Weight:470.60

Storage:

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Withaferin A Chemical Structure

CAS No.: 5119-48-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

NFκB

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	32.7 nM Compound: 1; WA	Antiproliferative activity against cisplatin-sensitive human A2780 cells measured after 96 hrs by MTT assay Antiproliferative activity against cisplatin-sensitive human A2780 cells measured after 96 hrs by MTT assay	[PMID: 31008605]
A549	IC₅₀	0.02 μg/mL Compound: WA	Cytotoxicity against human A549 cells by MTT method Cytotoxicity against human A549 cells by MTT method	[PMID: 17417907]
A549	IC₅₀	1.5 μM Compound: 9	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
A549	IC₅₀	6.6 μM Compound: 9	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
A549	IC₅₀	10.1 μM Compound: 1; WA	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	6.6 μM Compound: 1; WA	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
ACHN	IC₅₀	>2000 nM Compound: 2a	Sensitization of TRAIL-induced apoptosis in human ACHN cells assessed as reduction in cell viability preincubated for 2 hrs followed by addition of TRAIL measured after 18 hrs by MTS assay Sensitization of TRAIL-induced apoptosis in human ACHN cells assessed as reduction in cell viability preincubated for 2 hrs followed by addition of TRAIL measured after 18 hrs by MTS assay	[PMID: 28257574]
ARPE-19	IC₅₀	37 nM Compound: 1; WA	Cytotoxicity against human ARPE19 cells measured after 96 hrs by MTT assay Cytotoxicity against human ARPE19 cells measured after 96 hrs by MTT assay	[PMID: 31008605]
B16-F10	IC₅₀	0.29 μM Compound: 16	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay	[PMID: 22098611]
BXPC-3	IC₅₀	2.78 μM Compound: 46; WA	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay	[PMID: 31663736]
C3H 10T1/2	IC₅₀	4.9 μM Compound: 1	Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA	[PMID: 26169123]
DU-145	IC₅₀	2.5 μM Compound: 1	Cytotoxicity against human DU145 cells after 24 hrs by FMCA Cytotoxicity against human DU145 cells after 24 hrs by FMCA	[PMID: 26169123]
HaCaT	IC₅₀	0.5 μM Compound: 1	Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay	[PMID: 26169123]
HCT-116	IC₅₀	3.7 μM Compound: 75	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33445154]
HEK-293T	IC₅₀	299 nM Compound: 1	Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by resazurin dye based Alamar blue assay Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by resazurin dye based Alamar blue assay	[PMID: 29537263]
HeLa	IC₅₀	2.3 μM Compound: 9	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	3 μM Compound: 9	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	3 μM Compound: 1; WA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	6.3 μM Compound: 1; WA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Hep 3B2	IC₅₀	0.06 μg/mL Compound: WA	Cytotoxicity against human Hep3B cells by MTT method Cytotoxicity against human Hep3B cells by MTT method	[PMID: 17417907]
HepG2	IC₅₀	0.06 μg/mL Compound: WA	Cytotoxicity against human HepG2 cells by MTT method Cytotoxicity against human HepG2 cells by MTT method	[PMID: 17417907]
HFF	IC₅₀	>6.8 μM Compound: 8, WA	Cytotoxicity against HFF assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against HFF assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
HFF	IC₅₀	>6.8 μM Compound: 22	Cytotoxicity against human HFF cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human HFF cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
HFF	EC₅₀	>6800 nM Compound: 9	Cytotoxicity against HFF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against HFF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 36577036]
LNCaP	IC₅₀	0.87 μM Compound: 8, WA	Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human LNCAP cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
LNCaP	IC₅₀	0.87 μM Compound: 22	Cytotoxicity against human LNCAP cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human LNCAP cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
LNCaP	EC₅₀	870 nM Compound: 9	Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against androgen-sensitive human LNCaP cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 36577036]
MCF7	IC₅₀	0.05 μg/mL Compound: WA	Cytotoxicity against human MCF7 cells by MTT method Cytotoxicity against human MCF7 cells by MTT method	[PMID: 17417907]
MCF7	IC₅₀	0.6 μM Compound: 9	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	3.6 μM Compound: 9	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	6.3 μM Compound: 1	Cytotoxicity against human MCF7 cells after 24 hrs by FMCA Cytotoxicity against human MCF7 cells after 24 hrs by FMCA	[PMID: 26169123]
MCF7	IC₅₀	0.57 μM Compound: 8, WA	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
MCF7	IC₅₀	1.3 μM Compound: withaferin A	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 26492982]
MCF7	IC₅₀	0.57 μM Compound: 22	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
MCF7	IC₅₀	1.3 μM Compound: 1; WA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	3.6 μM Compound: 1; WA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MDA-MB-231	IC₅₀	0.02 μg/mL Compound: WA	Cytotoxicity against human MDA-MB-231 cells by MTT method Cytotoxicity against human MDA-MB-231 cells by MTT method	[PMID: 17417907]
MDA-MB-231	IC₅₀	0.54 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 24273633]
MDA-MB-231	IC₅₀	0.5 μM Compound: withaferin A	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 26492982]
MIA PaCa-2	IC₅₀	2.93 μM Compound: 46; WA	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTS assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTS assay	[PMID: 31663736]
MM1.S	IC₅₀	53 nM Compound: 1	Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
MRC5	IC₅₀	0.07 μg/mL Compound: WA	Cytotoxicity against human MRC5 cells by MTT method Cytotoxicity against human MRC5 cells by MTT method	[PMID: 17417907]
MRC5	IC₅₀	0.2 μM Compound: Withaferin A	Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay	[PMID: 23252848]
MRC5	IC₅₀	2.7 μM Compound: 1	Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay Cytotoxicity against human MRC5 cells after 72 hrs by MTS assay	[PMID: 24273633]
Multiple myeloma cancer stem cell	IC₅₀	649.7 nM Compound: WFA	Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay	[PMID: 30108696]
NCI-H460	IC₅₀	<0.4 μM Compound: 8, WA	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
NCI-H460	IC₅₀	<0.4 μM Compound: 22	Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
NCI-H929	IC₅₀	0.25 μM Compound: 1, WA	Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay	[PMID: 24625088]
PANC-1	IC₅₀	1.6 μM Compound: 1	Cytotoxicity against human PANC1 cells after 24 hrs by FMCA Cytotoxicity against human PANC1 cells after 24 hrs by FMCA	[PMID: 26169123]
PANC-1	IC₅₀	1.24 μM Compound: 46; WA	Antiproliferative activity against human PANC1 cells after 48 hrs by MTS assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTS assay	[PMID: 31663736]
PC-3	IC₅₀	0.41 μM Compound: 8, WA	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
PC-3	EC₅₀	410 nM Compound: 9	Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 36577036]
PC-3M	IC₅₀	0.41 μM Compound: 22	Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
RPMI-8226	IC₅₀	1.6 μM Compound: 1	Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay	[PMID: 34445874]
RPMI-8226	IC₅₀	258 nM Compound: 1	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
SF-268	IC₅₀	<0.4 μM Compound: 8, WA	Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
SF-268	IC₅₀	<0.4 μM Compound: 22	Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
SK-MEL-28	IC₅₀	4 μM Compound: 16	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay	[PMID: 22098611]
SK-MEL-28	IC₅₀	1 μM Compound: 1	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay	[PMID: 24273633]
SW480	IC₅₀	4.9 μM Compound: 75	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33445154]
U-251	IC₅₀	0.69 μM Compound: Withaferin A	Cytotoxicity against human U251 cells after 72 hrs by MTS assay Cytotoxicity against human U251 cells after 72 hrs by MTS assay	[PMID: 23252848]
U-87MG ATCC	IC₅₀	1.1 μM Compound: Withaferin A	Cytotoxicity against human U87 cells after 72 hrs by MTS assay Cytotoxicity against human U87 cells after 72 hrs by MTS assay	[PMID: 23252848]
Vero	IC₅₀	1.3 μM Compound: 9	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
Vero	IC₅₀	1.7 μM Compound: 9	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22705001]
Vero	IC₅₀	1.3 μM Compound: 1; WA	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	6.6 μM Compound: 1; WA	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]

In Vitro

Withaferin A has antiinflammatory activity, and potently inhibits NF-kB activation by preventing the TNF-induced activation of Ik-B kinase beta via a thioalkylation-sensitive redox mechanism^[1].
Withaferin A also has anticancer activity. Withaferin A targets the IF protein vimentin, causes aggregation of vimentin filaments in bovine aortic endothelial cells (BAECs) at 3 μM, and induces vimentin fragmentation in endothelial cells at 10 μM^[2].
Withaferin A (0.5, 1.5 μM) alone or incombination with cisplatin (CIS) dose-dependently reduces tumorigenic potential of ALDH1 positive cancer stem cells (CSCs)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Withaferin A (2 mg/kg, i.p.) shows potent angiogenesis inhibitory activity via vimentin in mice^[2]. Withaferin A (2 mg/kg) combined with cisplatin (CIS) regulates the expression of ALDH1 marker, and downregulates the expression of securin in tumors collected from mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 5119-48-2
Appearance Solid
Molecular Weight 470.60
Formula C₂₈H₃₈O₆
Color White to off-white
SMILES

C[C@]([C@](CC[C@@]1(C)[C@@]2([H])CC[C@]1([H])[C@@H]([C@@](O3)([H])CC(C)=C(CO)C3=O)C)([H])[C@@]2([H])C4)(C(C=C5)=O)[C@@]6([C@H]5O)[C@@H]4O6
Structure Classification
- Steroids
Initial Source
- Plants
- other families
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Publications (13)

All WBRT-PCRCell Imaging/StainingIFIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. [Abstract]

2026 Jan 16;11(1):33. PMID: 41545339
Adv Fiber Mater

2026 Mar 21.
Cell Death Differ

DR5/WDR12 balances p65 stability promoting sunitinib resistance in renal cell carcinoma. [Abstract]

2026 Mar 23. PMID: 41872532
J Exp Clin Cancer Res

Pharmacological induction of acetyl-CoA carboxylase 1 autophagic degradation attenuates lipid accumulation and cholangiocarcinoma progression. [Abstract]

2025 Nov 25;44(1):310. PMID: 41291880

Withaferin A purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 25;44(1):310. [Abstract]

Withaferin A (WA) treatment significantly reduced ACC1 protein levels in a time-dependent manner. Western blot analysis of ACC1 protein levels in HuCCT1 and RBE cells after treatment with 1 μM Withaferin A (WA) at 0, 12, 24, and 36 h was performed.

Withaferin A purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 25;44(1):310. [Abstract]

This study employed a combination of BODIPY 493/503 fluorescence staining and Oil Red O staining to detect lipid droplet content in RBE and HuCCT1 cells 24 h after Withaferin (WA) (2 µM) treatment.

Withaferin A purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Nov 25;44(1):310. [Abstract]

Witnaferin A (WA, 2 or 5 mg/kg; i.p.; once daily) significantly reduced tumor burden in cholangiocarcinoma (CCA) mice.
J Exp Clin Cancer Res

A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity. [Abstract]

2024 Feb 21;43(1):52. PMID: 38383479

Withaferin A purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2024 Feb 21;43(1):52. [Abstract]

OS cells were transfected with circKEAP1 shRNA and control vectors followed by treatment with Withaferin A (WFA) (5 µM). Control vectors, vimentin, or both circKEAP1 and vimentin were transfected into OS cells. Caspase-3 and PARP expression were determined by western blotting.
Cancer Cell Int

Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling. [Abstract]

2020 May 20;20:179. PMID: 32477009

Withaferin A purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2020 May 20;20:179. [Abstract]

PD-L1 protein levels in HepG2 cells treated with diferent concentration of NF-κB inhibitor, Withaferin A (WA, 25-100 nM).
Cancer Gene Ther

Demethoxycurcumin suppresses HK2-mediated glycolysis by targeting PTEN/Akt signaling. [Abstract]

2025 Oct 2. PMID: 41039015
Invest Ophthalmol Vis Sci

Targeted Activation of OGG1 Inhibits Paraptosis in Lens Epithelial Cells of Early Age-Related Cortical Cataract. [Abstract]

2025 Jan 2;66(1):29. PMID: 39804629
Aging

Bnip3 interacts with vimentin, an intermediate filament protein, and regulates autophagy of hepatic stellate cells. [Abstract]

2020 Dec 3;13(1):957-972. PMID: 33290258
Viruses

Cell Surface Vimentin Is an Attachment Factor That Facilitates Equine Arteritis Virus Infection In Vitro. [Abstract]

2026 Jan 15;18(1):113. PMID: 41600875
Vet Res

Vimentin affects inflammation and neutrophil recruitment in airway epithelium during Streptococcus suis serotype 2 infection. [Abstract]

2023 Jan 30;54(1):7. PMID: 36717839

Withaferin A purchased from MedChemExpress. Usage Cited in: Vet Res. 2023 Jan 30;54(1):7. [Abstract]

STEC pretreated with DMSO or 2.5 μM Withaferin A (WFA) for 1 h were infected with SS2 (MOI 50) for 2 h, and the transcription of IL-6 was determined using RT-qPCR.

Withaferin A purchased from MedChemExpress. Usage Cited in: Vet Res. 2023 Jan 30;54(1):7. [Abstract]

The effect of the vimentin inhibitor Withaferin A (WFA, 2.5 or 5 μM; 1 h) on the distribution of vimentin (green) in uninfected STEC was examined by immunofluorescence. The cell nuclei were stained with DAPI (blue). Scale bar, 100 μm.

Withaferin A purchased from MedChemExpress. Usage Cited in: Vet Res. 2023 Jan 30;54(1):7. [Abstract]

STEC pretreated with DMSO or 2.5 μM Withaferin A (WFA) for 1 h were infected with SS2 (MOI 50) for 2 h, and the transcription of NOD2 was determined using RT-qPCR. The results showed that destruction of vimentin filaments by Withaferin A (WFA) resulted in a failure of NOD2 transcription to increase in STEC.
Vet Microbiol

Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virus. [Abstract]

2025 Sep 15:310:110730. PMID: 40976146
The Hong Kong Polytechnic University

2023 Aug.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (106.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1249 mL

10.6247 mL

21.2495 mL

5 mM

0.4250 mL

2.1249 mL

4.2499 mL

10 mM

0.2125 mL

1.0625 mL

2.1249 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.83 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.83 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.83 mg/mL (1.76 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[3]

Ovarian epithelial cancer cell line A2780 is maintained in RPMI1640 medium supplemented with insulin (5 μg/mL), penicillin/streptomycin (100 IU/mL and 100 μg/mL respectively) and 10% fetal bovine serum (FBS) from Hyclone. Withaferin A, cisplatin (CIS) and other reagents are prepared in DMSO. Cisplatin is prepared fresh each time^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
Vimentin homozygous-deficient mice (Vim^−/−) and mice that are vimentin-heterozygous deficient (Vim^+/−) in the 129/Svev background are used in the assay. In brief, mice between 4 and 6 wk of age are anesthetized by intraperiteoneal (i.p.) injection of ketamine and xylazine. Corneas are topically anesthetized by application of proparacain eye drop, and 1 μL drop of dilute 0.15 M sodium hydroxide is applied for 1 min. The cornea is immediately washed extensively in saline solution, and corneal and limbal epithelium gently removed by scraping. The cornea is topically treated with atropine eye drop and covered with tobramycin and erythromycin antibiotic eye ointment. Withaferin A or 12-D WS (2 mg/kg solubilized in DMSO) or vehicle (DMSO) is injected i.p. in respective drug or control groups of mice after their recovery from corneal injury, and subsequently every day thereafter for a period of 10 days. Mice are humanely killed and eyes enucleated. The anterior segment half of eyes are dissected and corneal buttons are prepared. Corneal tissues are fixed in 100% acetone for 20 min, washed in PBS for 1 hr, and blocked for 18 hr in 1% BSA-PBS at 4°C. Cornea whole-mount staining is performed by incubating tissues in FITC-conjugated rat anti-mouse CD31 antibody (1:333 dilution in 1% BSA-PBS) for 12 hr, washed away for 24 hr at 4°C in 1% BSA-PBS, and affixed to glass slides with a coverslip. Fluorescent staining is visualized on microscope, and quantified by importing digital images to NIH ImageJ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kaileh M, et al. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem. 2007 Feb 16;282(7):4253-64. Epub 2006 Dec 6. [Content Brief]

[2]. Bargagna-Mohan P, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol. 2007 Jun;14(6):623-34. [Content Brief]

[3]. Kakar SS, et al. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells. Oncotarget. 2017 Aug 10;8(43):74494-74505. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1249 mL	10.6247 mL	21.2495 mL	53.1237 mL
	5 mM	0.4250 mL	2.1249 mL	4.2499 mL	10.6247 mL
	10 mM	0.2125 mL	1.0625 mL	2.1249 mL	5.3124 mL
	15 mM	0.1417 mL	0.7083 mL	1.4166 mL	3.5416 mL
	20 mM	0.1062 mL	0.5312 mL	1.0625 mL	2.6562 mL
	25 mM	0.0850 mL	0.4250 mL	0.8500 mL	2.1249 mL
	30 mM	0.0708 mL	0.3542 mL	0.7083 mL	1.7708 mL
	40 mM	0.0531 mL	0.2656 mL	0.5312 mL	1.3281 mL
	50 mM	0.0425 mL	0.2125 mL	0.4250 mL	1.0625 mL
	60 mM	0.0354 mL	0.1771 mL	0.3542 mL	0.8854 mL
	80 mM	0.0266 mL	0.1328 mL	0.2656 mL	0.6640 mL
	100 mM	0.0212 mL	0.1062 mL	0.2125 mL	0.5312 mL

Keywords

Withaferin A

13 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Withaferin A

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Withaferin A

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Withaferin A Related Classifications

Cat. No.: HY-N2065